Provided by Tiger Fintech (Singapore) Pte. Ltd.

Halozyme Therapeutics

64.27
+0.25000.39%
Volume:622.27K
Turnover:39.95M
Market Cap:7.92B
PE:18.74
High:64.60
Open:63.90
Low:63.51
Close:64.02
Loading ...

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates

Zacks
·
19 Feb

Halozyme Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
19 Feb

Halozyme Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
19 Feb

Halozyme Therapeutics Q4 Non-GAAP EPS, Revenue Increase

MT Newswires Live
·
19 Feb

Halozyme Therapeutics Q4 2024 Adj EPS $1.26 Beats $1.16 Estimate, Sales $298.00M Beat $288.24M Estimate

Benzinga
·
19 Feb

Halozyme Therapeutics Reiterates FY 2025 Guidance For EPS of $4.95-$5.35 on Revenue of $1.15-$1.225 Billion, vs FactSet Analyst Consensus of $4.90/Share on Revenue of $1.19 Billion

MT Newswires Live
·
19 Feb

Halozyme Therapeutics Inc - Reiterating 2025 Financial Guidance

THOMSON REUTERS
·
19 Feb

BRIEF-Halozyme Therapeutics Q4 Operating Expenses USD 122.507 Million

Reuters
·
19 Feb

Halozyme Therapeutics Q4 Operating Expenses USD 122.507 Million

THOMSON REUTERS
·
19 Feb

Halozyme Therapeutics Q4 Operating Income USD 175.501 Million

THOMSON REUTERS
·
19 Feb

Nexalin Technology’s HALO Clarity headset approved for use in trials by UCSD

TIPRANKS
·
18 Feb

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

GlobeNewswire
·
18 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
18 Feb

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Zacks
·
17 Feb

HALO Gears Up to Report Q4 Earnings: Here's What You Should Know

Zacks
·
14 Feb

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

Zacks
·
13 Feb